Trial Profile
A phase II study of obinutuzumab monotherapy in rituximab-refractory follicular lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms Zr-Obi
- 31 Oct 2019 Status changed from recruiting to completed.
- 28 Nov 2014 New trial record